Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | Journal Article | ||||||||||||
PMID | (39282524) | ||||||||||||
Authors | Hagedorn F, Göppner D, Hartmann S, Gattenlöhner S, Bräuninger A | ||||||||||||
Title | Detection of multiple activating NRAS variants under BRAF/MEK-inhibitor therapy in BRAF positive malignant melanoma using liquid biopsy. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E NRAS G13R | melanoma | predicted - resistant | Binimetinib + Encorafenib | Case Reports/Case Series | Actionable | In a clinical case study, NRAS G13R with progressively increasing variant allele frequency was identified in the circulating tumor DNA of a patient with metastatic melanoma harboring BRAF V600E who progressed on treatment with the combination of Mektovi (binimetinib) and Braftovi (encorafenib) (PMID: 39282524). | 39282524 |